# OnCo record cll-treatment-naive (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cll-treatment-naive/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cll-treatment-naive" ;
  schema:name "Chronic lymphocytic leukaemia, first treatment"@en ;
  schema:alternateName "Treatment-naive CLL"@en, "Front-line CLL"@en, "Previously untreated CLL"@en, "First-line CLL therapy"@en ;
  schema:description "Chronic lymphocytic leukaemia is treated only when it causes problems, and chemotherapy has gone. The first treatment is now either a BTK inhibitor taken indefinitely or a one-year course of venetoclax with obinutuzumab (CLL14), and the two can be combined for a fixed course."@en ;
  schema:url <https://onco.cc/cancers/cll-treatment-naive/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd20/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/ighv-status/>, <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/umrd/>, <https://onco.cc/terms/tumor-lysis-syndrome/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/>, <https://onco.cc/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/>, <https://onco.cc/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/> ;
  onco:pipeline <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/nemtabrutinib/>, <https://onco.cc/trials/celestial-tncll/>, <https://onco.cc/trials/cadance-304/>, <https://onco.cc/trials/bellwave-011/>, <https://onco.cc/ideas/idea-mrd-guided-stop-cll/>, <https://onco.cc/ideas/idea-btk-degrader-frontline/> ;
  onco:standardOfCare <https://onco.cc/terms/flow-cytometry/>, <https://onco.cc/terms/ighv-status/>, <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/trials/cll14/>, <https://onco.cc/trials/cll13-gaia/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/trials/glow/>, <https://onco.cc/trials/captivate/>, <https://onco.cc/trials/amplify/>, <https://onco.cc/pairings/venetoclax-plus-obinutuzumab/>, <https://onco.cc/pairings/btki-plus-venetoclax-fixed-duration/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/trials/elevate-tn/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/pairings/btki-ibrutinib-cardiac-caution/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/pairings/cit-in-del17p-caution/> .